Jaguar Health, Inc. (JAGX)
After hours:
| Previous Close | 0.1700 |
| Open | 0.1700 |
| Bid | 0.1720 x 700 |
| Ask | 0.1800 x 4200 |
| Day's Range | 0.1660 - 0.1947 |
| 52 Week Range | 0.0510 - 1.2200 |
| Volume | |
| Avg. Volume | 60,180,468 |
| Market Cap | 51.7M |
| Beta (5Y Monthly) | 1.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7900 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIRENapo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called "chemo mouth") in Q3 2024 Company to feature "Make Cancer Less Shitty" patient advocacy program at ONS Congress SAN FRANCISCO, CA ...
- ACCESSWIRE
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect ...
- ACCESSWIRE
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Jaguar planning to begin commercial launch in Q3 2024 for Gelclair®, the company's third prescription product Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive ...
